Financial Projections - The estimated net profit for 2025 is projected to be a loss between CNY 63.519 million and CNY 93.410 million, compared to a loss of CNY 85.856 million in the same period last year[3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss between CNY 61.160 million and CNY 89.942 million, compared to a loss of CNY 81.921 million in the same period last year[3]. Financial Expenses - Financial expenses are expected to be approximately CNY 25 million due to significant short-term and long-term borrowings[5]. - Depreciation and amortization of fixed assets are expected to impact the financials by about CNY 20 million[6]. - An estimated total of CNY 13 million will be required for impairment provisions on inventory, construction in progress, fixed assets, and development expenditures[6]. - Other operating expenses related to litigation and overdue interest are expected to be around CNY 22 million[7]. - The impact of non-recurring gains and losses on net profit is estimated to be about CNY 3 million[8]. Operational Status - The overall operating condition of the company is reported to be normal, with ongoing assessments for impairment provisions[9]. - The final impairment provision amounts will be determined after evaluation and audit by appointed assessment and audit agencies[9]. - The company aims to enhance profitability and achieve sustainable and stable operations[9].
香雪制药(300147) - 2025 Q4 - 年度业绩预告